biote BTMD 深 沪
等待开盘 10-06 09:30:00 美东时间
1.12
-0.030
-2.61%
华盛通- 最 高1.80
- 今 开1.15
- 成交量 13.13万股
- 最 低 1.10
- 昨 收 1.15
- 总市值 1032.81万
- 52周最高 3.26
- 市盈率 静 --
- 换手率 1.42%
- 52周最低 1.10
- 委 比 16.84%
- 总股本 922.15万
- 历史最高 12.08
- 量 比 1.81
- 振 幅 60.87%
- 历史最低 0.00
- 每 手 1
- 风险率 0.49%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NeuroSense Therapeutics Receives Nasdaq Noncompliance Notice; Co. Plans To Appeal
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases,
10-03 04:16
Regeneron Highlights Promising Ovarian Cancer, Muscle Preservation Trial Data
Regeneron reports positive trial data for ubamatamab in ovarian cancer and trevogrumab for muscle preservation during weight loss.
10-03 01:19
Monte Rosa Therapeutics Investigational Drug Shows Potential for Cardiovascular Disease
Monte Rosa Therapeutics reports positive Phase 1 trial data for MRT-8102 and outlines upcoming Phase 2 studies in inflammatory diseases.
10-02 00:44
Akari Therapeutics Submits PCT/US2026/45955 To Expand Its IP Portfolio
Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing disrupting payload, today announced the filing of PCT/US2026/45955, expanding
10-01 20:26
KALA Bio (KALA) Shares Soar 57% After Hours: Here's Why
KALA Bio shares surge after hours after signing an LOI to acquire a nationwide telehealth platform.
09-30 13:17
FibroBiologics Receives European Patent Titled Methods Of Enhancing Fibroblast Therapeutic Activity
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and
09-29 20:36
Silexion Therapeutics To Raise $837K Via Exercise Of ~3.217M Series E Warrants At $0.2603/Share
Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the
09-29 20:11
Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal
Zymeworks completes its Theravance Biopharma acquisition, boosts 2026 revenue guidance, and gains recurring revenue from YUPELRI sales.
09-29 01:05
The Insider Report: The Leaders Have Taken Off
Market Overview Stocks began their breakout to new all-time highs again, but it remains a highly selective environment. Only the Nasdaq hit a record high, as it finished up 2.06% on the week, and outperformed for the
09-28 20:46
Zymeworks Guides FY26 Total Sales, Including Collaboration Revenue From YUPELRI, Of $278M-$292M And Adjusted EBITDA Of $114M-$128M
Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the final
09-28 18:12
